Navigation Links
University of Mississippi Medical Center to lead in nationwide NIH-funded Alzheimer's study
Date:7/13/2010

JACKSON, Miss. The University of Mississippi Medical Center and four collaborating academic medical centers have received $26 million from the National Institutes of Health to identify risk factors for Alzheimer's disease and related forms of cognitive decline, said Dr. Thomas Mosley, UMMC professor of geriatric medicine and one of the new study's lead investigators.

The new funding will pay for the ARIC Neurocognitive Study, a comprehensive examination of thousands of patients, which will include detailed neurocognitive testing and brain imaging. The project builds on the influential Atherosclerosis Risk in Communities (ARIC) study, a large epidemiologic investigation of the risk factors for heart disease and stroke.

Using the new exam data and the wealth of information collected during ARIC's 20-plus years, the ARIC Neurocognitive Study is expected to further illuminate causes of dementia, giving researchers a unique window into early physiological changes that eventually culminate in Alzheimer's.

Of particular interest is the role that vascular risk factors including hypertension, diabetes and lifestyle experienced during middle age play in Alzheimer's and cognitive decline later in life.

"The new ARIC Neurocognitive Study will be one for the most comprehensive investigations to date into the role of vascular and related mid-life risk factors in Alzheimer's and cognitive decline," Mosley said.

He believes Alzheimer's disease likely isn't caused by a single factor, but rather by a complex process involving multiple factors interacting and accumulating over decades.

"Understanding the risk factors involved in this complex process may lead to new targets for treatment," he said. "It could also allow us to intervene at an earlier point with people who are at high risk for dementia, a time when preventative treatments may be most effective."

Researchers at UMMC will work with four collaborating primary study sites Johns Hopkins University, receiving about $4.6 million, Wake Forest University, receiving about $3.6 million, the University of Minnesota, receiving about $4.3 million, and the University of North Carolina at Chapel Hill receiving about $4.6 million.

Funded under UMMC's $9 million portion of the grant, Mosley's team includes scientists from the Mayo Clinic, Baylor College of Medicine, the University of Texas at Houston, Boston University and Erasmus University in the Netherlands.

The ARIC study has followed a group of roughly 16,000 participants for more than 20 years, from middle age into late life. Participants were initially recruited from four communities around the U.S., including approximately 4,000 African Americans from Jackson, Miss. Through a series of medical examinations over the years, ARIC participants have been extensively evaluated for diseases and factors including heart disease, hypertension and cognitive function.

Recent research has found African Americans may have a twofold or greater risk for Alzheimer's compared to whites. With one of the largest and most extensively evaluated African American study subgroups, the ARIC Neurocognitive Study will help illuminate the role of ethnic differences in relative risk for dementia.

Previous work by Mosley and ARIC colleagues has pointed to the importance of vascular risk factors in predicting decline in cognitive functions such as memory and processing speed. Using brain imaging, Mosley and colleagues have also shown brain changes, such as atrophy and silent strokes, are surprisingly common, even in middle-age adults and that these brain abnormalities begin to affect cognitive functions as early as middle age.

"A key question is whether brain changes we find in mid life predict dementia later in life and, if so, whether they are caused by potentially modifiable conditions, such as hypertension," Mosley said.

The ARIC Neurocognitive Study will also bring together state-of-the-art brain imaging and new genetic technology, powerful tools in the search for the causes of dementia.

"Rapidly advancing technology helps us address fundamental questions about how and why the brain ages," Mosley said. "We've put together a world-class team of leading experts representing a range of disciplines, including brain imaging, genetics, epidemiology, and neurology, to illuminate factors that increase risk as well as those that may protect against dementia."

In light of the aging U.S. population and a strong association between age and dementia risk, Mosley said it's paramount to improve clinical care and decode the factors that contribute to and protect against dementia.

"They represent some of the greatest challenges facing our medical system over the next 50 years," he said.

The ARIC Neurocognitive Study is the foundational study of UMMC's Memory Impairment and Neurodegenerative Dementia (MIND) Center, which Mosley directs.

A separate capital campaign at UMMC is under way to raise $8.9 million for the MIND Center. As the center develops, Mosley plans to recruit additional investigators to expand research in brain aging and dementia.

Due to the grant's scope, the ARIC Neurocognitive Study is co-funded by three NIH institutes: lead sponsor National Heart, Lung and Blood Institute; the National Institute of Neurological Disorders and Stroke; and the National Eye Institute.


'/>"/>

Contact: Jack Mazurak
jmazurak@umc.edu
601-984-1970
University of Mississippi Medical Center
Source:Eurekalert

Related medicine news :

1. Case Western Reserve University named International Center of Excellence for Malaria Research
2. Health care research: $1.6 million in new funding for University of Montreal
3. Tel Aviv University Fertility Research Confirms New York Center's DHEA Findings
4. Kilimani Sesame has positive impact on children in Tanzania: Johns Hopkins University study
5. University at Buffalo launches clinical trial of new multiple sclerosis treatment
6. Hebrew University added to Singapore research program
7. Pro Ana Versus Pro Recovery Sites: New Study by Johns Hopkins and Stanford University raises concerns.
8. Mayo Clinic and University of Illinois create research alliance
9. Scopus data play key role in statistical study at Kyoto University
10. University of Utah researchers fight genetic killer of infants and toddlers
11. University Hospitals Case Medical Center cardiologists discover cancer risks in blood pressure meds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... Sober College, the game-changing dual ... opening of the Sober College Robert Pfeifer Memorial Learning Center at its location ... was attended by an overwhelming amount of alumni, family, colleagues and friends of ...
(Date:12/9/2016)... ... ... "I had a terrible time trying to get my grandson to use his ... had a more child-friendly design, then children would be more likely to look forward ... avoid the need to deliver medication via a nebulizer mask. The design will not ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Company LLC, announced the first national #QuackGivesBack campaign which supported local breast ... was our first franchise-wide Quack Gives Back initiative, and we’re very ...
(Date:12/8/2016)... ... 08, 2016 , ... With the increasing demand for dental implants, the National ... campaign to inform dentists and patients about the safety issues related to dental restorations. ... in the U.S. is projected to reach $6.4 billion in 2018 with more than ...
(Date:12/8/2016)... N.J. (PRWEB) , ... December 08, 2016 , ... ... delivery technologies and development solutions for drugs, biologics and consumer health products, today ... PSCI was set up in 2006 as a non-profit organization to unite pharmaceutical ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 2016 Allergy Diagnostics Market: Scope and ... that are used to determine the presence of ... drugs etc. in the samples by determining the ... The report on global allergy diagnostics market, analyzes ... The report consists of an executive summary that ...
(Date:12/8/2016)... de dezembro de 2016  A Mederi Therapeutics Inc . anunciou aprovação ... não cirúrgico para a doença do refluxo gastroesofágico (DRGE). Foto -  ... ... Live Stretta procedure performed and broadcast during the Chinese ... Union Hospital , ...
(Date:12/8/2016)... Dec. 8, 2016  Valeant Pharmaceuticals International, Inc. ... ("Valeant") today announced positive results from a Phase ... assess the safety and efficacy of IDP-118 (halobetasol ... plaque psoriasis. Within the Phase ... to severe psoriasis, IDP-118 showed statistical significance to ...
Breaking Medicine Technology: